NASDAQ · Biotechnology · USD
Quoin Pharmaceuticals, Ltd. (QNRX) Stock Analysis
Quoin Pharmaceuticals, Ltd. (QNRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
QNRX Key Statistics
As of Oct 21, 2026Trading
- Open
- $4.01
- Previous Close
- $4.04
- Day's Range
- 3.99–4.19
- 52-Week Range
- 3.25–23.50
- Volume
- 7.75K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.75
Valuation
- Market Cap
- $19.17M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −5.67
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$15.80M
- Shares Outstanding
- 4.80M
- 1-Year Return
- −75.32%
Dividend and dates
- Avg Volume
- 544.58K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, QNRX closed at $3.99, −75.32% over 1 year.
Quoin Pharmaceuticals, Ltd. (QNRX) has a market capitalization of $19.17M.
In fiscal 2025, QNRX reported revenue of $0.00.
QNRX Stock Return by Calendar Year
Quoin Pharmaceuticals, Ltd. (QNRX) 10-year return: what $10,000 became
- 1 year
- $10,000 $2,468
- −75.32%
- 5 years
- $10,000 $0.53
- −99.99%
- 10 years
- $10,000 $0.10
- −99.999%
If you had invested $10,000 in Quoin Pharmaceuticals, Ltd. (QNRX) 10 years ago, at the close on October 21, 2016, it would have been worth $0.10 at the close on October 21, 2026: −99.999% in total, −68.43% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −72.35% |
| 2025 | −36.67% |
| 2024 | −86.73% |
| 2023 | −71.21% |
| 2022 | −93.76% |
| 2021 | −78.94% |
| 2020 | −2.70% |
| 2019 | −78.86% |
| 2018 | −70.00% |
| 2017 | +126.54% |
| 2016 (partial year) | −37.70% |
As of October 21, 2026.
QNRX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$15.80M | — |
| 2024 | $0.00 | −$8.96M | — |
| 2023 | $0.00 | −$8.69M | — |
| 2022 | $0.00 | −$9.38M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$16.29M | −$15.80M | — |
| 2024 | $0.00 | — | −$9.53M | −$8.96M | — |
| 2023 | $0.00 | — | −$9.38M | −$8.69M | — |
| 2022 | $0.00 | — | −$9.26M | −$9.38M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
YahooQuoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome
BenzingaCanaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18
BenzingaQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
YahooQuoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome
BenzingaBTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14
Benzinga
All 17 articles ↓Show fewer ↑
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
YahooQuoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue
BenzingaLake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
BenzingaQuoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
YahooQuoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
YahooCORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
YahooQuoin in line for second priority review voucher if rare paediatric drug approved
pharmaceutical-technology.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
YahooFDA Grants Rare Pediatric Disease Designation For Quoin Pharma’s Lead Asset, QRX003, For Treatment Of Peeling Skin Syndrome
BenzingaQuoin Pharmaceuticals Stock Surges Friday: What's Happening?
BenzingaQuoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B